Enlivex Therapeutics (ENLV) 6-K 22 Aug 22 Condensed Consolidated Financial Statements Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	ENLIVEX THERAPEUTICS LTD.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001596812
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity File Number	001-36578
Entity Address, Address Line One	14 Einstein Street
Entity Address, Address Line Two	Nes Ziona
Entity Address, Country	IL
Entity Address, Postal Zip Code	7403618

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 20,151	$ 11,202
Short term deposits	42,334	10,004
Marketable securities		62,924
Prepaid expenses and other receivables	2,453	2,199
Cash held with respect to CVR Agreement	113	113
Total Current Assets	65,051	86,442
Non-Current Assets
Property and equipment, net	6,517	2,530
Other assets	5,773	6,174
Total Non-Current Assets	12,290	8,704
TOTAL ASSETS	77,341	95,146
Current Liabilities
Accounts payable trade	667	878
Accrued expenses and other liabilities	3,433	3,727
CVR holders	113	113
Total Current Liabilities	4,213	4,718
Non-Current Liabilities
Other long-term Liabilities	4,642	5,389
Total Non-Current Liabilities	4,642	5,389
Commitments and Contingent Liabilities
TOTAL LIABILITIES	8,855	10,107
SHAREHOLDERS’ EQUITY
Ordinary shares of NIS 0.4 par value: Authorized: 45,000,000 shares as of June 30, 2022 and December 31, 2021; Issued and outstanding: 18,381,052 and 18,331,507 as of June 30 and December 31, 2021;	2,113	2,107
Additional paid in capital	135,375	133,796
Foreign currency translation adjustments	1,101	1,101
Accumulated deficit	(70,103)	(51,965)
TOTAL SHAREHOLDERS’ EQUITY	68,486	85,039
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 77,341	$ 95,146

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - ₪ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Ordinary shares, par value (in New Shekels per share)	₪ 0.4	₪ 0.4
Ordinary shares, authorized	45,000,000	45,000,000
Ordinary shares, Issued	18,381,052	18,331,507
Ordinary shares, outstanding	18,381,052	18,331,507

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues
Operating expenses:
Research and development expenses	4,110	2,539	8,792	5,036
General and administrative expenses	1,761	1,269	3,483	2,574
Total operating expenses	5,871	3,808	12,275	7,610
Operating loss	(5,871)	(3,808)	(12,275)	(7,610)
Other income/(expense), net	(4,042)	700	(5,863)	1,302
Net (loss)	(9,913)	(3,108)	(18,138)	(6,308)
Other comprehensive income (loss)
Exchange differences arising from translating financial statements from functional to presentation currency		2,055		(733)
Total other comprehensive income (loss)		2,055		(733)
Total comprehensive (loss)	$ (9,913)	$ (1,053)	$ (18,138)	$ (7,041)
Basic & diluted (loss) per share (in Dollars per share)	$ (0.54)	$ (0.17)	$ (0.99)	$ (0.36)
Weighted average number of shares outstanding (in Shares)	18,375,206	18,305,882	18,372,521	17,397,860

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Basic & diluted (loss) per share (in Dollars per share)	$ (0.54)	$ (0.17)	$ (0.99)	$ (0.36)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Ordinary Shares		Additional Paid-in Capital	Currency translation reserve	Accumulated deficit	Total
Balance at Dec. 31, 2020	$ 1,646		$ 70,361	$ 977	$ (37,497)	$ 35,487
Balance (in Shares) at Dec. 31, 2020	14,587,934
Issuance of shares and warrants for cash consideration of $57,629 net of $4,455 issuance costs	$ 352		52,822			53,174
Issuance of shares and warrants for cash consideration of $57,629 net of $4,455 issuance costs (in Shares)	2,848,629
Exercise of options	$ 2		38			40
Exercise of options (in Shares)	13,435
Exercise of warrants	$ 104		7,598			7,702
Exercise of warrants (in Shares)	855,813
Stock based compensation			190			190
Other comprehensive loss				(2,788)		(2,788)
Net loss					(3,200)	(3,200)
Balance at Mar. 31, 2021	$ 2,104		131,009	(1,811)	(40,697)	90,605
Balance (in Shares) at Mar. 31, 2021	18,305,811
Exercise of options		[1]	2			2
Exercise of options (in Shares)	375
Stock based compensation			652			652
Other comprehensive loss				2,055		2,055
Net loss					(3,108)	(3,108)
Balance at Jun. 30, 2021	$ 2,104		131,663	244	(43,805)	90,206
Balance (in Shares) at Jun. 30, 2021	18,306,186
Balance at Dec. 31, 2021	$ 2,107		133,796	1,101	(51,965)	85,039
Balance (in Shares) at Dec. 31, 2021	18,331,507
Restricted stock units vested	$ 4		(4)
Restricted stock units vested (in Shares)	34,295
Exercise of options	$ 1		49			50
Exercise of options (in Shares)	7,625
Stock based compensation			788			788
Net loss					(8,225)	(8,225)
Balance at Mar. 31, 2022	$ 2,112		134,629	1,101	(60,190)	77,652
Balance (in Shares) at Mar. 31, 2022	18,373,427
Exercise of options	$ 1		49			50
Exercise of options (in Shares)	7,625
Stock based compensation			697			697
Net loss					(9,913)	(9,913)
Balance at Jun. 30, 2022	$ 2,113		$ 135,375	$ 1,101	$ (70,103)	$ 68,486
Balance (in Shares) at Jun. 30, 2022	18,381,052
[1] Less than $1

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) (Parentheticals) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Cash consideration	$ 57,629
Net of issuance costs	$ 4,455

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net (loss)	$ (18,138)	$ (6,308)
Adjustments required to reflect net cash used in operating activities:
Depreciation	364	239
Non-cash operating lease expenses	411	107
Share-based compensation	1,485	842
Loss (income) on marketable securities and short-term bank deposits	4,886	(1,583)
Changes in operating asset and liability items:
Decrease in prepaid expenses and other receivables	(205)	(195)
Increase (decrease) in accounts payable trade	(211)	101
Increase (decrease) in accrued expenses and other liabilities	(307)	153
Operating lease liabilities	(827)	(106)
Net cash (used in) provided by operating activities	(12,542)	(6,750)
Cash flows from investing activities
Purchase of property and equipment	(4,351)	(472)
Release (investment) in short-term bank deposits	(35,234)	19,563
Purchases of marketable securities	(1,608)	(85,695)
Proceeds from sales of marketable securities	62,549	19,217
Net cash provided by (used in) investing activities	21,356	(47,387)
Cash flows from financing activities
Proceeds from issuance of shares and warrants net of $4,455 issuance expenses		53,174
Proceeds from exercise of warrants		7,702
Proceeds from exercise of options	100	42
Net cash provided by financing activities	100	60,918
Increase (decrease) in cash and cash equivalents	8,914	6,781
Cash and cash equivalents - beginning of period	11,636	7,012
Exchange rate differences on cash and cash equivalents		(210)
Cash and cash equivalents - end of period	20,550	13,583
Non-cash transactions:
Warrants issued in settlement of issuance costs to a placement agent		2,095
Supplemental disclosures of cash flow information:
Cash paid for taxes
Cash paid (received) for interest, net	$ 45	$ 62

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement of Cash Flows [Abstract]
Issuance expenses	$ 4,455	$ 4,455

General

General	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL a. Enlivex Therapeutics Ltd. (the “ Parent we us our Company Enlivex Therapeutics R&D Ltd. (“ Enlivex R&D In January 2015, Enlivex Therapeutics Inc. was incorporated in the State of Delaware as a wholly owned subsidiary of the Parent. On June 21, 2021 Enlivex Therapeutics RDO Ltd. was incorporated in Israel as a wholly owned subsidiary of the Parent. The Company is a clinical stage macrophage reprogramming immunotherapy company, developing Allocetra TM AllocetraTM is based on the discoveries of Professor Dror Mevorach, an expert on immune activity, macrophage activation and clearance of dying (apoptotic) cells, in his laboratory in the Hadassah University Hospital located in the State of Israel. The Company’s ordinary shares, NIS 0.40 per share (“ Ordinary Shares b. Financial Resources The Company devotes substantially all of its efforts toward research and development activities and raising capital to support such activities. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. Research and development activities have required significant capital investment since the Company’s inception. The Company expects that its operations will require additional cash investment to pursue the Company’s research and development activities, including preclinical studies, formulation development, clinical trials and related drug manufacturing. The Company has not generated any revenues or product sales and has not achieved profitable operations or positive cash flow from operations. The Company has incurred net losses since its inception, and, as of June 30, 2022, had an accumulated deficit of $70,103 thousand. The Company expects to continue to incur losses for at least the next several years, and the Company will need to raise additional debt or equity financing or enter into partnerships to fund its development. If the Company is not able to achieve its funding requirements, it may be required to reduce discretionary spending, may not be able to continue the development of its product candidates or may be required to delay its development programs, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. There can be no assurances that additional financing will be secured or, if secured, will be on favorable terms. The ability of the Company to transition to profitability in the longer term is dependent on developing products and product revenues to support its expenses. The Company’s management and board of directors (the “ Board

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These unaudited condensed consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2021 Annual Report on Form 20-F, as filed with the SEC on April 29, 2022. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2021 financial information has been derived from the Company’s audited financial statements. Use of Estimates The preparation of interim financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts in the consolidated balance sheets and statements of operations, it also requires that management exercise its judgment in applying the Company’s accounting policies. On an ongoing basis, management evaluates its estimates, including estimates related to its stock-based compensation expense and implicit interest rate on new lease liabilities. Significant estimates in these interim financial statements include estimates made for accrued research and development expenses and stock-based compensation expenses. Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the U.S. dollar because the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Until September 30, 2021, the functional currency of Enlivex R&D was the New Israeli Shekel (“NIS”). Balances related to non-monetary assets and liabilities are based on translated amounts as of the date of the change, and non-monetary assets acquired and liabilities incurred after September 30, 2021 were translated at the approximate exchange rate prevailing at the date of the transaction. Transactions included in the statement of income for the three and six month periods ended June 30, 2022 were translated at the approximate exchange rate in effect at the respective times of the transactions. Transactions included in the statement of income for the three and six month periods ended June 30, 2021 were translated at average exchange rates during the applicable period. Gains or losses resulting from translation adjustments for the three and six month periods ended June 30, 2021 are reported in other comprehensive income (loss). one U.S. dollar = 3.50 NIS and 3.11 NIS as of June 30, 2022 and December 31, 2021, respectively. The U.S. dollar increased (decreased) against the NIS: 10.20%, 12.54%, (2.22%) and 1.4% in the three and six month periods ended June 30, 2022 and 2021, respectively. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging: Contracts in Entity’s Own Equity (Subtopic 815-40) Recently Issued Accounting Pronouncements Not Yet Adopted The Company has evaluated other recently issued accounting pronouncements and does not currently believe that any of these pronouncements will have a material impact on its condensed consolidated financial statements and related disclosures. Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021. Marketable Securities. The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in mutual funds that are classified based on the nature of their underlying securities and their availability for use in current operations. The Company’s marketable equity securities are measured at fair value with gains and losses recognized in other income/(expense), net. Net (loss) income recognized on equity securities for the three and six month periods ended June 30, 2022 and 2021 was $0, $(1,982), $1,195 and $1,583 thousand of which $0, $0, $950 and $1,342 thousand, respectively, were not realized.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	6 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
CASH, CASH EQUIVALENTS AND RESTRICTED CASH	NOTE 3 – CASH, CASH EQUIVALENTS AND RESTRICTED CASH June 30, December 31, (in thousands) 2022 2021 Cash held in banks $ 2,133 $ 1,199 Bank deposits in U.S.$ (annual average interest rates 3.02% and 0.1%) 18,018 10,003 Total cash and cash equivalents 20,151 11,202 Cash held with respect to CVR Agreement 113 113 Restricted cash – noncurrent – Other assets 286 321 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 20,550 $ 11,636

Short Term Deposits

Short Term Deposits	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
SHORT TERM DEPOSITS	NOTE 4 – SHORT TERM DEPOSITS June 30, December 31, (in thousands) 2022 2021 Bank deposits in U.S.$ and NIS (average annual interest rates 0.7% and 0.6%) $ 42,334 $ 10,004 Total short-term deposits $ 42,334 $ 10,004

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: June 30, December 31, (in thousands) 2022 2021 Cost: Laboratory equipment $ 2,253 $ 1,891 Computers 276 256 Office furniture & equipment 218 192 Leasehold improvements 5,464 1,521 8,211 3,860 Accumulated depreciation: Laboratory equipment 1,176 960 Computers 170 138 Office furniture & equipment 22 15 Leasehold improvements 326 217 1,694 1,330 Depreciated cost $ 6,517 $ 2,530 Depreciation expenses for the three and six month periods ended June 30, 2022 and 2021 were $176, $364, $122 and $239 thousand, respectively.

Other Assets

Other Assets	6 Months Ended
	Jun. 30, 2022
Other Assets [Abstract]
OTHER ASSETS	NOTE 6 – OTHER ASSETS June 30, December 31, (in thousands) 2022 2021 Restricted cash $ 286 $ 321 Long-term prepaid expenses 118 164 Right-of-Use assets, net 5,369 5,689 $ 5,773 $ 6,174

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 7 – ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, (in thousands) 2022 2021 Vacation, convalescence and bonus accruals $ 528 $ 1,068 Employees and payroll related 639 519 Short term operating lease liabilities 629 617 Accrued expenses and other 1,637 1,523 $ 3,433 $ 3,727

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
LEASES	NOTE 8 – LEASES The Company is a party to operating leases for its corporate offices, laboratory space and vehicles. The Company’s real property operating leases have remaining lease terms of up to 3.25 years, some of which include options to extend the leases for up to five years. Six months ended June 30, (in thousands) 2022 2021 The components of lease expense were as follows: Operating leases expenses $ 517 $ 139 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 478 $ 135 Non-cash activity: Right of use assets obtained in exchange for new operating lease liabilities $ 91 $ 29 June 30, December 31, (in thousands ) 2022 2021 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 6,420 $ 6,329 Accumulated amortization 1,051 640 Operating lease Right-of-Use assets, net $ 5,369 $ 5,689 Lease liabilities – current - Accounts payable and accrued liabilities $ 629 $ 617 Lease liabilities – noncurrent 4,642 5,389 Total operating lease liabilities $ 5,271 $ 6,006 Weighted average remaining lease term in years 8.1 8.6 Weighted average annual discount rate 3.6 % 3.6 % Maturities of operating lease liabilities as of June 30, 2022, were as follows: 2022 (after June 30) $ 386 2023 786 2024 679 2025 714 2026 and onwards 3,497 Total undiscounted lease liability $ 6,062 Less: Imputed interest $ (791 ) Present value of lease liabilities $ 5,271

Commitments and Contingent Liab

Commitments and Contingent Liabilities	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 9 – COMMITMENTS AND CONTINGENT LIABILITIES The Company is required to pay royalties to the State of Israel (represented by the Israeli Innovation Authority (the “ IIA The gross amount of grants received by the Company from the IIA, including accrued interest as of June 30, 2022, was approximately $8.9 million. As of June 30, 2022, the Company had not paid any royalties to the IIA. In January 2022, the Company submitted a new grant application to the IIA to approve the expenditure of $4.8 million of its clinical development program for the prevention of cytokine storms and organ dysfunction associated with sepsis for a period commencing January 1, 2022 and ending December 31, 2022 (the “2022 Sepsis Grant Application”). In May 2020, the IIA selected this program to receive a non-dilutive grant of approximately $1.0 million for expenses associated with the Company’s ongoing sepsis clinical Phase II trial.

Equity

Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
EQUITY	NOTE 10 – EQUITY All Company warrants are classified as a component of shareholders’ equity because such warrants are free standing financial instruments that are legally detachable, separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise, requires physical settlement and do not provide any guarantee of value or return. Number of Weighted average exercise Outstanding January 1, 2022 704,355 $ 13.18 Forfeited and expired (502,104 ) $ 9.50 Outstanding and exercisable June 30, 2022 202,251 $ 23.31 Comprised as follows: Number of Warrants Exercise Issuance Expiration 22,750 $ 10 February 26, 2020 February 24, 2025 160,727 $ 25 February 12, 2021 February 9, 2026 18,774 $ 25 February 17, 2021 February 9, 2026 202,251

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 11 – SHARE-BASED COMPENSATION a) As of June 30, 2022, 4,150,704 Ordinary Shares were authorized for issuance to employees, directors and consultants under the 2019 Equity Incentive Plan, of which 1,189,363 shares were available for future grant. b) The following table contains information concerning options granted under the existing equity incentive plans: Three months ended June 30, 2022 2021 Number of Weighted Number of Weighted Outstanding at beginning of period 2,399,622 $ 5.95 1,870,485 $ 5.54 Granted - $ - 310,500 $ 12.57 Forfeited and expired (3,000 ) $ 5.34 (2,685 ) $ 7.38 Exercised (7,625 ) $ 6.49 (375 ) $ 4.68 Outstanding at end of period 2,388,997 $ 5.95 2,177,925 $ 6.54 Exercisable at end of period 1,728,623 $ 5.10 1,404,809 $ 5.50 Non-vested at beginning of period 722,749 $ 7.67 544,163 $ 6.04 Granted - $ - 310,500 $ 12.57 Vested (59,375 ) $ (8.78) (78,862 ) $ 13.15 Forfeited) (3,000 ) $ (5.34) (2,685 ) $ 7.38 Non-vested at the end of period 660,374 $ 7.59 773,116 $ 8.19 Six months ended June 30, 2022 2021 Number of Weighted Number of Weighted Outstanding at beginning of period 2,142,547 $ 6.02 1,884,420 $ 5.52 Granted 264,700 $ 5.48 310,500 $ 12.57 Forfeited and expired (3,000 ) $ 5.34 (3,185 ) $ 6.96 Exercised (15,250 ) $ 6.49 (13,810 ) $ 2.99 Outstanding at end of period 2,388,997 $ 5.95 2,177,925 $ 6.54 Exercisable at end of period 1,728,623 $ 5.10 1,404,809 $ 5.50 Non vested at beginning of period 529,082 $ 8.69 601,227 $ 5.93 Granted 264,700 $ 5.48 310,500 $ 12.57 Forfeited and expired (3,000 ) $ 5.34 (135,426 ) $ 8.22 vested (130,408 ) $ 7.82 (3,185 ) $ 6.96 Outstanding at end of period 660,374 $ 7.59 773,116 $ 8.19 During the three and six month periods ended June 30, 2022 and 2021, the Company recognized $509, $1,074, $603 and $778 thousand, respectively, of share-based compensation expenses related to stock options. As of June 30, 2022, the total unrecognized estimated compensation cost related to outstanding non-vested stock options was $1,780 thousand, which is expected to be recognized over a weighted average period of 1.5 years. c) Set forth below is data regarding the range of exercise prices and remaining contractual life for all options outstanding at June 30, 2022: Exercise price Number outstanding Remaining Intrinsic No. of options (in thousands ) $ 2.69 649,883 2.92 1,189,284 649,883 $ 3.66 250,000 7.84 214,250 180,556 $ 4.68 55,500 7.75 - 27,750 $ 5.35 231,200 9.75 - $ 6.22 634,177 5.00 - 620,879 $ 6.49 15,250 0.03 - - $ 8.19 150,000 7.38 - 75,000 $ 8.23 20,000 9.39 - - $ 8.30 15,000 9.10 - - $ 9.02 40,500 8.38 - 10,125 $ 10.12 12,126 6.43 - 9,700 $ 12.21 2,421 6.74 - 1,816 $ 12.23 250,000 8.91 - 111,111 $ 14.00 60,500 8.82 - 40,333 $ 21.40 1,940 7.07 - 970 $ 90.16 500 2.42 - 500 2,388,997 $ 1,403,534 1,728,623 d) The following table contains information concerning restricted stock units granted under the existing equity incentive plans: Three months ended June 30, 2022 2021 Number of Weighted Number of Weighted Nonvested at beginning of period 184,787 $ 10.02 48,375 $ 14.67 Granted - $ - 13,750 $ 10.28 Vested (3,437 ) $ 10.28 - $ - Forfeited - - (2,000 ) $ 14.67 Nonvested at end of period 181,350 $ 10.02 60,125 $ 13.67 Six months ended June 30, 2022 2021 Number of Weighted Number of Weighted Nonvested at beginning of period 229,331 $ 10.08 - $ - Granted - $ - 62,125 $ 13.7 Vested (47,981 ) $ 10.29 - $ - Forfeited - $ - (2,000 ) $ 14.67 Nonvested at end of period 181,350 $ 10.02 60,125 $ 13.67 The Company estimates the fair value of restricted stock units based on the closing sales price of the Ordinary Shares on the date of grant (or the closing bid price, if no sales were reported). For the three and six month periods ended June 30, 2022 and 2021, the Company recognized $188, $411, $49 and $64 thousand, respectively, of share-based compensation expense related to restricted stock units. Total share-based compensation expense related to restricted stock units not yet recognized as of June 30, 2022 was $889 thousand, which is expected to be recognized over a weighted average period of 1.5 years. e) The following table summarizes share-based compensation expenses related to grants under the existing equity incentive plans included in the statements of operations: Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Research & development $ 119 $ 358 $ 509 $ 446 General & administrative 578 294 976 396 Total $ 697 $ 652 $ 1,485 $ 842

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 12 – FAIR VALUE MEASUREMENT The Company’s financial assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of June 30, 2022 and December 31, 2021: June 30, 2022 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 20,550 $ 20,550 $ - $ - Short term deposits 42,334 42,334 - - Cash held with respect to CVR Agreement 113 113 - - Restricted cash 286 286 - - Total financial assets $ 63,283 $ 63,283 $ - $ - December 31, 2021 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 11,202 $ 11,202 $ - $ - Short term deposits 10,004 10,004 - - Cash held with respect to CVR Agreement 113 113 - - Marketable securities 62,924 62,924 - - Restricted cash 321 321 - - Total financial assets $ 84,564 $ 84,564 $ - $ -

Events Subsequent to the Balanc

Events Subsequent to the Balance Sheet Date	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 13 – EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE The Company evaluated all events and transactions that occurred subsequent to the balance sheet date and prior to the date on which these unaudited condensed consolidated financial statements were issued and determined that there were no events that necessitated disclosure:

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2021 Annual Report on Form 20-F, as filed with the SEC on April 29, 2022. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2021 financial information has been derived from the Company’s audited financial statements.
Use of Estimates	Use of Estimates The preparation of interim financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts in the consolidated balance sheets and statements of operations, it also requires that management exercise its judgment in applying the Company’s accounting policies. On an ongoing basis, management evaluates its estimates, including estimates related to its stock-based compensation expense and implicit interest rate on new lease liabilities. Significant estimates in these interim financial statements include estimates made for accrued research and development expenses and stock-based compensation expenses.
Functional Currency and Translation to The Reporting Currency	Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the U.S. dollar because the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Until September 30, 2021, the functional currency of Enlivex R&D was the New Israeli Shekel (“NIS”). Balances related to non-monetary assets and liabilities are based on translated amounts as of the date of the change, and non-monetary assets acquired and liabilities incurred after September 30, 2021 were translated at the approximate exchange rate prevailing at the date of the transaction. Transactions included in the statement of income for the three and six month periods ended June 30, 2022 were translated at the approximate exchange rate in effect at the respective times of the transactions. Transactions included in the statement of income for the three and six month periods ended June 30, 2021 were translated at average exchange rates during the applicable period. Gains or losses resulting from translation adjustments for the three and six month periods ended June 30, 2021 are reported in other comprehensive income (loss). one U.S. dollar = 3.50 NIS and 3.11 NIS as of June 30, 2022 and December 31, 2021, respectively. The U.S. dollar increased (decreased) against the NIS: 10.20%, 12.54%, (2.22%) and 1.4% in the three and six month periods ended June 30, 2022 and 2021, respectively.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging: Contracts in Entity’s Own Equity (Subtopic 815-40)
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted The Company has evaluated other recently issued accounting pronouncements and does not currently believe that any of these pronouncements will have a material impact on its condensed consolidated financial statements and related disclosures.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021.
Marketable Securities.	Marketable Securities. The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company invests its excess cash primarily in mutual funds that are classified based on the nature of their underlying securities and their availability for use in current operations. The Company’s marketable equity securities are measured at fair value with gains and losses recognized in other income/(expense), net. Net (loss) income recognized on equity securities for the three and six month periods ended June 30, 2022 and 2021 was $0, $(1,982), $1,195 and $1,583 thousand of which $0, $0, $950 and $1,342 thousand, respectively, were not realized.

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	6 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents and restricted cash	June 30, December 31, (in thousands) 2022 2021 Cash held in banks $ 2,133 $ 1,199 Bank deposits in U.S.$ (annual average interest rates 3.02% and 0.1%) 18,018 10,003 Total cash and cash equivalents 20,151 11,202 Cash held with respect to CVR Agreement 113 113 Restricted cash – noncurrent – Other assets 286 321 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 20,550 $ 11,636

Short Term Deposits (Tables)

Short Term Deposits (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of short term deposits	June 30, December 31, (in thousands) 2022 2021 Bank deposits in U.S.$ and NIS (average annual interest rates 0.7% and 0.6%) $ 42,334 $ 10,004 Total short-term deposits $ 42,334 $ 10,004

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment, net consists of the following: June 30, December 31, (in thousands) 2022 2021 Cost: Laboratory equipment $ 2,253 $ 1,891 Computers 276 256 Office furniture & equipment 218 192 Leasehold improvements 5,464 1,521 8,211 3,860 Accumulated depreciation: Laboratory equipment 1,176 960 Computers 170 138 Office furniture & equipment 22 15 Leasehold improvements 326 217 1,694 1,330 Depreciated cost $ 6,517 $ 2,530

Other Assets (Tables)

Other Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Other Assets [Abstract]
Schedule of other assets	June 30, December 31, (in thousands) 2022 2021 Restricted cash $ 286 $ 321 Long-term prepaid expenses 118 164 Right-of-Use assets, net 5,369 5,689 $ 5,773 $ 6,174

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of accrued expenses and other liabilities	June 30, December 31, (in thousands) 2022 2021 Vacation, convalescence and bonus accruals $ 528 $ 1,068 Employees and payroll related 639 519 Short term operating lease liabilities 629 617 Accrued expenses and other 1,637 1,523 $ 3,433 $ 3,727

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of operating lease	Six months ended June 30, (in thousands) 2022 2021 The components of lease expense were as follows: Operating leases expenses $ 517 $ 139 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 478 $ 135 Non-cash activity: Right of use assets obtained in exchange for new operating lease liabilities $ 91 $ 29
Schedule of operating lease related activities	June 30, December 31, (in thousands ) 2022 2021 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 6,420 $ 6,329 Accumulated amortization 1,051 640 Operating lease Right-of-Use assets, net $ 5,369 $ 5,689 Lease liabilities – current - Accounts payable and accrued liabilities $ 629 $ 617 Lease liabilities – noncurrent 4,642 5,389 Total operating lease liabilities $ 5,271 $ 6,006 Weighted average remaining lease term in years 8.1 8.6 Weighted average annual discount rate 3.6 % 3.6 %
Schedule of maturities of operating lease liabilities	Maturities of operating lease liabilities as of June 30, 2022, were as follows: 2022 (after June 30) $ 386 2023 786 2024 679 2025 714 2026 and onwards 3,497 Total undiscounted lease liability $ 6,062 Less: Imputed interest $ (791 ) Present value of lease liabilities $ 5,271

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of number of ordinary shares upon exercise	Number of Weighted average exercise Outstanding January 1, 2022 704,355 $ 13.18 Forfeited and expired (502,104 ) $ 9.50 Outstanding and exercisable June 30, 2022 202,251 $ 23.31
Schedule of changes in exercisable ordinary shares warrants	Number of Warrants Exercise Issuance Expiration 22,750 $ 10 February 26, 2020 February 24, 2025 160,727 $ 25 February 12, 2021 February 9, 2026 18,774 $ 25 February 17, 2021 February 9, 2026 202,251

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of employees and directors stock options	Three months ended June 30, 2022 2021 Number of Weighted Number of Weighted Outstanding at beginning of period 2,399,622 $ 5.95 1,870,485 $ 5.54 Granted - $ - 310,500 $ 12.57 Forfeited and expired (3,000 ) $ 5.34 (2,685 ) $ 7.38 Exercised (7,625 ) $ 6.49 (375 ) $ 4.68 Outstanding at end of period 2,388,997 $ 5.95 2,177,925 $ 6.54 Exercisable at end of period 1,728,623 $ 5.10 1,404,809 $ 5.50 Non-vested at beginning of period 722,749 $ 7.67 544,163 $ 6.04 Granted - $ - 310,500 $ 12.57 Vested (59,375 ) $ (8.78) (78,862 ) $ 13.15 Forfeited) (3,000 ) $ (5.34) (2,685 ) $ 7.38 Non-vested at the end of period 660,374 $ 7.59 773,116 $ 8.19 Six months ended June 30, 2022 2021 Number of Weighted Number of Weighted Outstanding at beginning of period 2,142,547 $ 6.02 1,884,420 $ 5.52 Granted 264,700 $ 5.48 310,500 $ 12.57 Forfeited and expired (3,000 ) $ 5.34 (3,185 ) $ 6.96 Exercised (15,250 ) $ 6.49 (13,810 ) $ 2.99 Outstanding at end of period 2,388,997 $ 5.95 2,177,925 $ 6.54 Exercisable at end of period 1,728,623 $ 5.10 1,404,809 $ 5.50 Non vested at beginning of period 529,082 $ 8.69 601,227 $ 5.93 Granted 264,700 $ 5.48 310,500 $ 12.57 Forfeited and expired (3,000 ) $ 5.34 (135,426 ) $ 8.22 vested (130,408 ) $ 7.82 (3,185 ) $ 6.96 Outstanding at end of period 660,374 $ 7.59 773,116 $ 8.19
Schedule of exercise prices and remaining contractual life	Exercise price Number outstanding Remaining Intrinsic No. of options (in thousands ) $ 2.69 649,883 2.92 1,189,284 649,883 $ 3.66 250,000 7.84 214,250 180,556 $ 4.68 55,500 7.75 - 27,750 $ 5.35 231,200 9.75 - $ 6.22 634,177 5.00 - 620,879 $ 6.49 15,250 0.03 - - $ 8.19 150,000 7.38 - 75,000 $ 8.23 20,000 9.39 - - $ 8.30 15,000 9.10 - - $ 9.02 40,500 8.38 - 10,125 $ 10.12 12,126 6.43 - 9,700 $ 12.21 2,421 6.74 - 1,816 $ 12.23 250,000 8.91 - 111,111 $ 14.00 60,500 8.82 - 40,333 $ 21.40 1,940 7.07 - 970 $ 90.16 500 2.42 - 500 2,388,997 $ 1,403,534 1,728,623
Schedule of restricted stock units	Three months ended June 30, 2022 2021 Number of Weighted Number of Weighted Nonvested at beginning of period 184,787 $ 10.02 48,375 $ 14.67 Granted - $ - 13,750 $ 10.28 Vested (3,437 ) $ 10.28 - $ - Forfeited - - (2,000 ) $ 14.67 Nonvested at end of period 181,350 $ 10.02 60,125 $ 13.67 Six months ended June 30, 2022 2021 Number of Weighted Number of Weighted Nonvested at beginning of period 229,331 $ 10.08 - $ - Granted - $ - 62,125 $ 13.7 Vested (47,981 ) $ 10.29 - $ - Forfeited - $ - (2,000 ) $ 14.67 Nonvested at end of period 181,350 $ 10.02 60,125 $ 13.67
Schedule of share-based compensation expenses related to grants under the equity incentive plan	Three months ended Six months ended (in thousands) 2022 2021 2022 2021 Research & development $ 119 $ 358 $ 509 $ 446 General & administrative 578 294 976 396 Total $ 697 $ 652 $ 1,485 $ 842

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities measured at fair value on a recurring basis	June 30, 2022 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 20,550 $ 20,550 $ - $ - Short term deposits 42,334 42,334 - - Cash held with respect to CVR Agreement 113 113 - - Restricted cash 286 286 - - Total financial assets $ 63,283 $ 63,283 $ - $ - December 31, 2021 (in thousands) Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 11,202 $ 11,202 $ - $ - Short term deposits 10,004 10,004 - - Cash held with respect to CVR Agreement 113 113 - - Marketable securities 62,924 62,924 - - Restricted cash 321 321 - - Total financial assets $ 84,564 $ 84,564 $ - $ -

General (Details)

General (Details) $ in Thousands	Jun. 30, 2022 USD ($)	Jun. 30, 2022 ₪ / shares	Dec. 31, 2021 USD ($)
General (Textual)
Aggregate of ordinary shares | ₪ / shares		₪ 40
Accumulated deficit | $	$ (70,103)		$ (51,965)

Significant Accounting Polici_2

Significant Accounting Policies (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021
Significant Accounting Policies (Details) [Line Items]
Net (loss) income recognized	$ 0	$ 950	$ 0	$ 1,342
NIS [Member]
Significant Accounting Policies (Details) [Line Items]
Exchange rate for 1 $ = NIS	3.5		3.5		3.11
Increase (decrease) against the NIS	10.20%	(2.22%)	(12.54%)	(1.40%)
Equity Securities [Member]
Significant Accounting Policies (Details) [Line Items]
Net (loss) income recognized	$ 0	$ 1,195	$ (1,982)	$ 1,583

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of cash and cash equivalents and restricted cash - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Schedule Of Cash And Cash Equivalents And Restricted Cash Abstract
Cash held in banks	$ 2,133	$ 1,199
Bank deposits in U.S.$ (annual average interest rates 3.02% and 0.1%)	18,018	10,003
Total cash and cash equivalents	20,151	11,202
Cash held with respect to CVR Agreement	113	113
Restricted cash – noncurrent – Other assets	286	321
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 20,550	$ 11,636	$ 13,583	$ 7,012

Cash, Cash Equivalents and Re_4

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of cash and cash equivalents and restricted cash (Parentheticals)	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Cash And Cash Equivalents And Restricted Cash Abstract
Annual average interest rates	3.02%	0.10%

Short Term Deposits (Details) -

Short Term Deposits (Details) - Schedule of short term deposits - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Short Term Deposits Abstract
Bank deposits in U.S.$ and NIS (average annual interest rates 0.7% and 0.6%)	$ 42,334	$ 10,004
Total short-term deposits	$ 42,334	$ 10,004

Short Term Deposits (Details)_2

Short Term Deposits (Details) - Schedule of short term deposits (Parentheticals)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Short Term Deposits Abstract
Bank deposits in(average annual interest rates	0.70%	0.60%

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 176	$ 122	$ 364	$ 239

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost	$ 8,211	$ 3,860
Total accumulated depreciation	1,694	1,330
Depreciated cost	6,517	2,530
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	2,253	1,891
Total accumulated depreciation	1,176	960
Computers [Member]
Property, Plant and Equipment [Line Items]
Cost	276	256
Total accumulated depreciation	170	138
Office furniture & equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	218	192
Total accumulated depreciation	22	15
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	5,464	1,521
Total accumulated depreciation	$ 326	$ 217

Other Assets (Details) - Schedu

Other Assets (Details) - Schedule of other assets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Other Assets Abstract
Restricted cash	$ 286	$ 321
Long-term prepaid expenses	118	164
Right-of-Use assets, net	5,369	5,689
Total	$ 5,773	$ 6,174

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses and other liabilities - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Accrued Expenses And Other Liabilities Abstract
Vacation, convalescence and bonus accruals	$ 528	$ 1,068
Employees and payroll related	639	519
Short term operating lease liabilities	629	617
Accrued expenses and other	1,637	1,523
Accrued expenses and other liabilities, Total	$ 3,433	$ 3,727

Leases (Details)

Leases (Details)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Operating lease remaining term	3 years 3 months

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
The components of lease expense were as follows:
Operating leases expenses	$ 517	$ 139
Supplemental consolidated cash flow information related to operating leases follows:
Cash used in operating activities	478	135
Non-cash activity:
Right of use assets obtained in exchange for new operating lease liabilities	$ 91	$ 29

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of operating lease related activities - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Operating Lease Related Activities Abstract
Other assets - Right-of-Use assets	$ 6,420	$ 6,329
Accumulated amortization	1,051	640
Operating lease Right-of-Use assets, net	5,369	5,689
Lease liabilities – current - Accounts payable and accrued liabilities	629	617
Lease liabilities – noncurrent	4,642	5,389
Total operating lease liabilities	$ 5,271	$ 6,006
Weighted average remaining lease term in years	8 years 1 month 6 days	8 years 7 months 6 days
Weighted average annual discount rate	3.60%	3.60%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of maturities of operating lease liabilities $ in Thousands	Jun. 30, 2022 USD ($)
Schedule Of Maturities Of Operating Lease Liabilities Abstract
2022 (after June 30)	$ 386
2023	786
2024	679
2025	714
2026 and onwards	3,497
Total undiscounted lease liability	6,062
Less: Imputed interest	(791)
Present value of lease liabilities	$ 5,271

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Commitments and Contingent Liabilities (Details) [Line Items]
Total gross amount of grants including accrued interest (in Dollars)	$ 8.9
Minimum [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of royalties in sales	3%
Maximum [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Percentage of royalties in sales	5%

Equity (Details) - Schedule of

Equity (Details) - Schedule of number of ordinary shares upon exercise - Warrants [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Equity (Details) - Schedule of number of ordinary shares upon exercise [Line Items]
Number of Warrants Outstanding beginning balance | shares	704,355
Weighted average exercise price Outstanding beginning balance | $ / shares	$ 13.18
Number of Warrants Forfeited and expired | shares	(502,104)
Weighted average exercise price Forfeited and expired | $ / shares	$ 9.5
Number of Warrants Outstanding ending balance | shares	202,251
Weighted average exercise price Outstanding ending balance | $ / shares	$ 23.31

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of changes in exercisable ordinary shares warrants	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Warrants	202,251
Exercise Price 10 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	22,750
Exercise price per share | $ / shares	$ 10
Issuance date	Feb. 26, 2020
Expiration date	Feb. 24, 2025
Exercise Price 25 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	160,727
Exercise price per share | $ / shares	$ 25
Issuance date	Feb. 12, 2021
Expiration date	Feb. 09, 2026
Exercise Price 25 [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	18,774
Exercise price per share | $ / shares	$ 25
Issuance date	Feb. 17, 2021
Expiration date	Feb. 09, 2026

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Compensation (Details) [Line Items]
Ordinary shares authorized (in Shares)	4,150,704		4,150,704
Share-based compensation expenses	$ 509	$ 1,074	$ 603	$ 778
Employees' Stock Option [Member]
Share-Based Compensation (Details) [Line Items]
Total unrecognized estimated compensation cost				$ 1,780
Weighted average period				1 year 6 months
Consultants' stock options [Member]
Share-Based Compensation (Details) [Line Items]
Total unrecognized estimated compensation cost			$ 889
Weighted average period			1 year 6 months
2019 Equity Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Future grant share (in Shares)	1,189,363		1,189,363
Restricted Stock [Member]
Share-Based Compensation (Details) [Line Items]
Share-based compensation expenses	$ 188	$ 411	$ 49	$ 64

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of employees and directors stock options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Employees And Directors Stock Options Abstract
Number of options, Outstanding at beginning of period	2,399,622	1,870,485	2,142,547	1,884,420
Weighted average exercise price, Outstanding at beginning of period	$ 5.95	$ 5.54	$ 6.02	$ 5.52
Number of options, Granted		310,500	264,700	310,500
Weighted average exercise price, Granted		$ 12.57	$ 5.48	$ 12.57
Number of options, Forfeited and expired	(3,000)	(2,685)	(3,000)	(3,185)
Weighted average exercise price, Forfeited and expired	$ 5.34	$ 7.38	$ 5.34	$ 6.96
Number of options, Exercised	(7,625)	(375)	(15,250)	(13,810)
Weighted average exercise price, Exercised	$ 6.49	$ 4.68	$ 6.49	$ 2.99
Number of options, Outstanding at end of period	2,388,997	2,177,925	2,388,997	2,177,925
Weighted average exercise price, Outstanding at end of period	$ 5.95	$ 6.54	$ 5.95	$ 6.54
Number of options, Exercisable at end of period	1,728,623	1,404,809	1,728,623	1,404,809
Weighted average exercise price, Exercisable at end of period	$ 5.1	$ 5.5	$ 5.1	$ 5.5
Number of options, Non-vested at beginning of period	722,749	544,163	529,082	601,227
Weighted average exercise price, Non-vested at beginning of period	$ 7.67	$ 6.04	$ 8.69	$ 5.93
Number of options, Granted		310,500	264,700	310,500
Weighted average exercise price, Granted		$ 12.57	$ 5.48	$ 12.57
Number of options, Vested	(59,375)	(78,862)	(130,408)	(3,185)
Weighted average exercise price, Vested	$ (8.78)	$ 13.15	$ 7.82	$ 6.96
Number of options, Forfeited	(3,000)	(2,685)	(3,000)	(135,426)
Weighted average exercise price, Forfeited	$ (5.34)	$ 7.38	$ 5.34	$ 8.22
Number of options, Non-vested at the end of period	660,374	773,116	660,374	773,116
Weighted average exercise price, Non-vested at the end of period	$ 7.59	$ 8.19	$ 7.59	$ 8.19

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of exercise prices and remaining contractual life $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding	2,388,997
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 1,403,534
No. of options exercisable	1,728,623
Exercise Price One [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 2.69
Number of options outstanding	649,883
Remaining contractual Life (in years)	2 years 11 months 1 day
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 1,189,284
No. of options exercisable	649,883
Exercise Price Two [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.66
Number of options outstanding	250,000
Remaining contractual Life (in years)	7 years 10 months 2 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 214,250
No. of options exercisable	180,556
Exercise Price Three [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.68
Number of options outstanding	55,500
Remaining contractual Life (in years)	7 years 9 months
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	27,750
Exercise Price Four [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 5.35
Number of options outstanding	231,200
Remaining contractual Life (in years)	9 years 9 months
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Five [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 6.22
Number of options outstanding	634,177
Remaining contractual Life (in years)	5 years
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	620,879
Exercise Price Six [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 6.49
Number of options outstanding	15,250
Remaining contractual Life (in years)	10 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Seven [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 8.19
Number of options outstanding	150,000
Remaining contractual Life (in years)	7 years 4 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	75,000
Exercise Price Eight [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 8.23
Number of options outstanding	20,000
Remaining contractual Life (in years)	9 years 4 months 20 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Nine [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 8.3
Number of options outstanding	15,000
Remaining contractual Life (in years)	9 years 1 month 6 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Ten [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 9.02
Number of options outstanding	40,500
Remaining contractual Life (in years)	8 years 4 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	10,125
Exercise Price Eleven [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 10.12
Number of options outstanding	12,126
Remaining contractual Life (in years)	6 years 5 months 4 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	9,700
Exercise Price Twelve [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 12.21
Number of options outstanding	2,421
Remaining contractual Life (in years)	6 years 8 months 26 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	1,816
Exercise Price Thirteen [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 12.23
Number of options outstanding	250,000
Remaining contractual Life (in years)	8 years 10 months 28 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	111,111
Exercise Price Fourteen [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 14
Number of options outstanding	60,500
Remaining contractual Life (in years)	8 years 9 months 25 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	40,333
Exercise Price Fifteen [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 21.4
Number of options outstanding	1,940
Remaining contractual Life (in years)	7 years 25 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	970
Exercise Price Sixteen [Member] | Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 90.16
Number of options outstanding	500
Remaining contractual Life (in years)	2 years 5 months 1 day
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	500

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of restricted stock units - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Restricted Stock Units Abstract
Number of shares, Nonvested at beginning of period	184,787	48,375	229,331
Weighted average grant date fair value, Nonvested at beginning of period	$ 10.02	$ 14.67	$ 10.08
Number of shares, Granted		13,750		62,125
Weighted average grant date fair value, Granted		$ 10.28		$ 13.7
Number of shares, Vested	(3,437)		(47,981)
Weighted average grant date fair value, Vested	$ 10.28		$ 10.29
Number of shares, Forfeited		(2,000)		(2,000)
Weighted average grant date fair value, Forfeited		$ 14.67		$ 14.67
Number of shares, Nonvested at end of period	181,350	60,125	181,350	60,125
Weighted average grant date fair value, Nonvested at end of period	$ 10.02	$ 13.67	$ 10.02	$ 13.67

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Schedule of share-based compensation expenses related to grants under the equity incentive plan - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 697	$ 652	$ 1,485	$ 842
Research & development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	119	358	509	446
General & administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 578	$ 294	$ 976	$ 396

Fair Value Measurement (Details

Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	$ 20,550	$ 11,202
Short term deposits	42,334	10,004
Cash held with respect to CVR Agreement	113	113
Marketable securities		62,924
Restricted cash	286	321
Total financial assets	63,283	84,564
Level 1 [Member]
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	20,550	11,202
Short term deposits	42,334	10,004
Cash held with respect to CVR Agreement	113	113
Marketable securities		62,924
Restricted cash	286	321
Total financial assets	63,283	84,564
Level 2 [Member]
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Cash held with respect to CVR Agreement
Marketable securities
Restricted cash
Total financial assets
Level 3 [Member]
Fair Value Measurement (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Cash held with respect to CVR Agreement
Marketable securities
Restricted cash
Total financial assets